Kasper P. Kepp

Technical University of Denmark

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (12)

Bruno Falissard

Professor Biostatistics

Université Paris-Saclay

FRANCE

View details

Michaéla Schippers

Associate Professor

RSM Erasmus University

NETHERLANDS

View details

Jonas Björk

Lund University

SWEDEN

View details

Mona-Elisabeth Revheim

Oslo University Hospital

NORWAY

View details

Kristoffer Torbjørn Bæk

Technical University of Denmark

DENMARK

View details

Perrine Janiaud

University of Bern

SWITZERLAND

View details

Holger J. Schünemann

McMaster University

CANADA

View details

Stefano L. Sensi

ITALY

View details

Tea Lallukka

University of Helsinki

FINLAND

View details

Niclas Sandström

University of Helsinki

FINLAND

View details

Ioana Alina Cristea

Associate Professor

University of Padova

ITALY

View details

Anton Nilsson

Associate professor

Lund University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kasper P. Kepp

Research Interests

Contact this professor

Articles (22)

Advocacy by nonprofit scientific institutions needs to be evidence-based: a case study

Communicating scientific evidence: drugs for Alzheimer’s disease as a case study

Comment on “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US”

Excess mortality in Denmark, Finland, Norway and Sweden during the COVID-19 pandemic 2020–2022

Zero-covid advocacy during the COVID-19 pandemic: a case study of views on Twitter/X

Are lecanemab and donanemab disease-modifying therapies?

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit

Lecanemab and Donanemab as Therapies for Alzheimer's Disease: An Illustrated Perspective on the Data

Panel stacking is a threat to consensus statement validity

Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42

Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village

Cause-specific excess mortality in Denmark, Finland, Norway, and Sweden during the COVID-19 pandemic 2020–2022: a study using nationwide population data

Stability and expression of SARS-CoV-2 spike-protein mutations

The contribution of population age-sex structure to the excess mortality estimates of 2020–2021 in Denmark, Finland, Iceland, Norway, and Sweden

The amyloid cascade hypothesis: an updated critical review

Modelling SARS-CoV-2 spike-protein mutation effects on ACE2 binding

Estimates of excess mortality for the five Nordic countries during the COVID-19 pandemic 2020-2021.

Assessment of AlphaFold2 for Human Proteins via Residue Solvent Exposure.

Data set and fitting dependencies when estimating protein mutant stability: Toward simple, balanced, and interpretable models

Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case

Bioinorganic Chemistry of Zinc in Relation to the Immune System

Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview

Collaborators (12)

Bruno Falissard

Michaéla Schippers

Jonas Björk

Mona-Elisabeth Revheim

Kristoffer Torbjørn Bæk

Perrine Janiaud

Holger J. Schünemann

Stefano L. Sensi

Tea Lallukka

Niclas Sandström

Ioana Alina Cristea

Anton Nilsson

Make your next move.